Introduction
Several recent studies have reported good linear correlations between phenytoin concentrations in mixed saliva and those in serum, cerebrospinal fluid, and plasma water (the ultrafiltrate or free fraction) (Bochner, Hooper, Sutherland, Eadie & Tyrer, 1974; Cook, Amerson, Poole, Lesser & O'Tuama, 1976; Paxton, Rowell, Ratcliffe, Lambie, Nanda, Melville & Johnson, 1976; Reynolds, Ziroyanis, Jones & Smith, 1976) . These studies suggest that phenytoin in saliva may be in equilibrium with the free therapeutically active phenytoin in plasma water. Reynolds et aL (1976) also suggested that phenytoin therapy could be more appropriately monitored by measurement of salivary, rather than plasma, drug concentrations especially in circumstances such as renal failure when protein binding is disturbed. Obviously, if measurements of phenytoin salivary concentrations are to have any practical value in routine monitoring of therapy, the method of collection should be as simple as possible. In the four reports mentioned, mixed saliva was collected by voiding into vials without exogenous stimulation apart from the subjects studied by Bochner et aL (1974) who chewed on a small piece of Teflon and those by Reynolds et al. (1976) who received 10 mg citric acid to stimulate salivary flow. With the exception of Reynolds et al. (1976) who reported a 6% decrease in salivary phenytoin concentration after stimulation, the effect of exogenous stimulation on salivary concentration was not investigated. All four studies were also conducted using mixed saliva, which consists of parotid, submandibular, sublingual and minor gland saliva together with oral bacteria, desquamated epithelial cells and gingival fluid. No information was provided regarding the origin of the phenytoin in mixed saliva; whether it was secreted by one particular salivary gland or was exuding from the gingival tissue. If estimation of phenytoin concentration in saliva is to be accepted as a reliable index of the biologically active fraction of phenytoin, the dependency of its concentration on the type and volume of saliva produced and on degree of stimulation and salivary flow rate must be determined. It is the aim of this study to investigate these factors and also to investigate whether changes in serum concentrations are reflected by corresponding changes in salivary concentrations.
Methods
The subjects in this study were freely consenting healthy male laboratory staff aged 20-40 years, who received oral doses of phenytoin sodium BP and samples were taken as follows:
1 Seven subjects received a 100 or 300 mg oral dose of phenytoin. Two subjects received both doses. Simultaneous blood and mixed saliva samples were obtained at hourly intervals for the first 12 h and then thrice daily where possible over the subsequent 3 to 5 days.
2 Three subjects received an oral dose of 300 mg phenytoin. Twenty-four hours later, blood, mixed, parotid and submandibular saliva fractions were collected at hourly intervals for 4 hours. The mixed saliva was collected after chewing washed rubber bands for several minutes (Shannon, 1962) . For the parotid and submandibular fractions, five sequential collections of 1 ml each were obtained where possible at each hourly interval, after stimulation of salivary flow rate by application to the dorsum of the tongue of 1 ml of 10% citric acid solution every 30 s (Stephen & Speirs, 1976 
Results
After simultaneous collection of mixed saliva and blood, semi-log concentration-time plots of phenytoin in saliva and serum showed good parallelism after the initial 14 h in all seven subjects at various doses as exemplified in Figure 1 . During the initial 14 h period variations in phenytoin concentrations were observed in both mixed saliva and serum which were not due to experimental error. These variations could not be attributed to periods of fluid or food intake and did not seem to follow a regular pattern. Parallelism between the concentrations of phenytoin in mixed saliva and serum was demonstrated by the similar half-lives in these fluids. Half-life values shown in Table 1 were calculated from the con- centrations of phenytoin in saliva and serum from 30-100 h after administration of the phenytoin dose. Elimination of phenytoin appeared monoexponential within this period. However, although the forms of the serum and mixed salivary concentration-time curves were very similar, significantly greater variations were observed in the mixed salivary levels of phenytoin than in the serum levels. This was not entirely due to the greater coefficient of variation for the salivary phenytoin assay compared with the serum assay. No significant trends in the mixed saliva: serum concentration ratio were detected, either with time or with serum concentration.
Concentrations of phenytoin were also determined in five sequential 1 ml samples from separate submandibular and parotid salivary secretions obtained from three subjects 24 h after administration of phenytoin (300 mg). These concentrations together with the corresponding concentrations observed in mixed saliva and serum are shown in Table 2 . Submandibular samples were not obtained from one subject (JGR) due to a broad lingual frenum which precluded the use of the submandibular collection device. The concentrations of phenytoin in the parotid and submandibular fluids were not significantly different but were significantly higher (P < 0.001 ) than the concentrations in the mixed salivary secretions when compared by Student's t-test on paired observations. A similar comparison of paired values for the percentage ratio of mixed salivary phenytoin concentration: serum concentration (mnean ± s.d. 13.1% ± 2.7, n = 12) and the percentage ratio for parotid and submandibular phenytoin concentration: serum concentration (mean ± s.d. 14.5% ± 1.2, n = 20) were also significantly different (P < 0.001). No significant trends in the phenytoin concentrations in either the parotid or submandibular fractions were observed in the five sequential 1 ml samples obtained over a period of 5-10 min ( Table 2) . The mean ± s.d. value (6.0% ± 2.0, n = 12) for the coefficients of variation of repeated analysis (n = 4) of the single mixed saliva samples, and the mean ± s.d. value (6.3% ± 2.6, n = 20) of the Table 3 . Further investigation of the dependency of salivary phenytoin concentration on flow rate was carried out on one subject. As accurate estimation of mixed salivary flow rate is exceedingly difficult this was not attempted, but Figure 2 These results, together with reports of saliva phenytoin concentrations comparable to cerebrospinal fluid and free phenytoin concentrations (Bochner et al., 1974; Cook et al., 1976; Paxton et al., 1976) , suggest that it is the free drug which is in equilibrium between serum and saliva. The ease of diffusion across the lipid membranes will depend on lipid solubility characteristics and the degree of ionization of the drug. Since phenytoin has an ionization constant (pKa) of 9.2 and the pH of plasma is 7.4 and that of saliva between 6-8, depending on gland type and flow rate, very little drug should be ionized in either fluid. Also phenytoin can be considered to possess good lipid solubility characteristics since it is soluble in alcohol, chloroform and ether. Thus the movement of phenytoin across lipid membranes would not be hindered. Distribution at equilibrium which is dependent on serum and salivary pHs will ensure that salivary concentrations will be the same as that of free phenytoin in plasma water, assuming that saliva is essentially an albumin-free fluid. 
